COMP <GO>
EOCN vs ERNA // REVENUE GROWTH (YOY)
Eocene Ltd. (NASDAQ) VS. Ernexa Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EOCN 1
— ERNA 2
■ METRIC PARITY
LAST: $3.22 (+0.62%) • MKT CAP: $3.4M
revenue-growth
—
LAST: $2.11 (+6.57%) • MKT CAP: $3.4M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EOCN VS. ERNA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EOCN | ERNA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ERNA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.3 | 32.3 | +10.93 | EOCN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.4M | $3.4M | -$90.5K | ERNA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EOCN REV | ERNA REV | EOCN GROSS % | ERNA GROSS % | EOCN FCF | ERNA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$6.3M | -$7.1M |
| FY 2024 | $0 | $582.0K | — | 83.5% | -$5.9M | -$16.2M |
| FY 2023 | $0 | $68.0K | — | — | -$6.1M | -$20.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EOCN // BETA —
ERNA // BETA —